Wagner Wealth Management LLC increased its position in shares of Eli Lilly And Co (NYSE:LLY) by 49.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,837 shares of the company’s stock after purchasing an additional 945 shares during the quarter. Wagner Wealth Management LLC’s holdings in Eli Lilly And Co were worth $304,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently modified their holdings of the stock. Principal Financial Group Inc. increased its position in Eli Lilly And Co by 8.3% during the first quarter. Principal Financial Group Inc. now owns 1,807,947 shares of the company’s stock worth $139,881,000 after buying an additional 138,746 shares in the last quarter. Trust Co. of Vermont increased its position in Eli Lilly And Co by 10.1% during the second quarter. Trust Co. of Vermont now owns 9,708 shares of the company’s stock worth $828,000 after buying an additional 893 shares in the last quarter. Xact Kapitalforvaltning AB increased its position in Eli Lilly And Co by 3.9% during the second quarter. Xact Kapitalforvaltning AB now owns 205,241 shares of the company’s stock worth $17,513,000 after buying an additional 7,697 shares in the last quarter. First Citizens Bank & Trust Co. purchased a new position in Eli Lilly And Co during the second quarter worth $296,000. Finally, Pennsylvania Trust Co increased its position in Eli Lilly And Co by 9.2% during the second quarter. Pennsylvania Trust Co now owns 12,995 shares of the company’s stock worth $1,109,000 after buying an additional 1,100 shares in the last quarter. 76.17% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have weighed in on LLY shares. BMO Capital Markets raised their price target on Eli Lilly And Co from $78.00 to $80.00 and gave the stock a “$89.43” rating in a research report on Thursday, July 19th. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b+” rating in a research report on Tuesday. Cowen set a $105.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a research report on Tuesday, July 24th. Cantor Fitzgerald set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a research report on Tuesday, July 24th. Finally, Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Wednesday, July 18th. Nine analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $111.19.
Shares of NYSE:LLY traded down $0.12 during midday trading on Friday, reaching $109.98. The company’s stock had a trading volume of 353,724 shares, compared to its average volume of 4,616,905. The company has a market cap of $113.74 billion, a P/E ratio of 25.70, a P/E/G ratio of 1.69 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $116.61.
Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 44.13% and a net margin of 1.85%. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter last year, the firm earned $1.05 earnings per share. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. Sell-side analysts expect that Eli Lilly And Co will post 5.57 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be issued a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.05%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is currently 52.57%.
ILLEGAL ACTIVITY WARNING: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2018/11/09/eli-lilly-and-co-lly-stake-increased-by-wagner-wealth-management-llc.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Stock Selection – What is cash flow?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.